Icon plc, a healthcare intelligence and clinical research organization, reported the latest release of its digital platform. The platform supports integration of Icon patient, site, and sponsor services with the delivery of harmonized data and can be customized for any study design, from traditional to fully decentralized.

The Icon Digital Platform enables patient services throughout clinical trials including a patient mobile app, eConsent, eCOA, direct data capture for in-home services, televisits and digital health technology management. It offers the technical functionality, standard capability, and integrated services, in one platform, that enable flexibility for any clinical trial.

Among the features of the Icon Digital Platform include the eCOA module which is pre-loaded with the validated Mapi Research Trust library, instruments and translations, reducing eCOA set-up during study start-up.  It also supports the integration of the FIRECREST Site Portal for training and communications, Clinical Trial Tokenisation, digital outreach for patient recruitment and laboratory data, along with reporting dashboards and analytics.

In a prepared statement, the company said that connecting and engaging patients in decentralized clinical trials is of increasing importance and ICON offers a wide range of customized, clinical, and technical concierge services to support users of the digital platform including enrolment and on-boarding, technology and device logistics support, adherence check-ins and study completion services.

The platform deployment and management are governed by Icon’s regulatory framework, and this, along with its global scalability capabilities, including language localization, reduces regulatory compliance risk for sponsors.

Steve Cutler, CEO, Icon, said, “This newest version of the Digital Platform enables the efficient capture and delivery of quality data from a range of decentralized clinical trial services. Its ease of use enables greater patient centricity, reducing the barriers to trial participation and enhancing the equity, diversity, and inclusion of patient populations.”